|
|
Volumn 16, Issue 1, 2010, Pages 9-10
|
|
Could we use clinical benefit to evaluate the effects of chinese medicine on the treatment of cancer?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANASTROZOLE;
FLUOROURACIL;
GEMCITABINE;
ADVANCED CANCER;
BREAST CANCER;
CANCER CHEMOTHERAPY;
CANCER PALLIATIVE THERAPY;
CANCER RADIOTHERAPY;
CANCER STAGING;
CANCER THERAPY;
CHINESE MEDICINE;
HUMAN;
OVERALL SURVIVAL;
PANCREAS CANCER;
POSTMENOPAUSE;
PRIORITY JOURNAL;
QUALITY OF LIFE;
RADIATION INJURY;
SCORING SYSTEM;
SHORT SURVEY;
SURVIVAL TIME;
TREATMENT RESPONSE;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
HUMANS;
MEDICINE, CHINESE TRADITIONAL;
NEOPLASMS;
PALLIATIVE CARE;
PROGNOSIS;
QUALITY OF LIFE;
RADIOTHERAPY;
RISK ASSESSMENT;
TREATMENT OUTCOME;
|
|
EID: 76649111424
PISSN: 16720415
EISSN: None
Source Type: Journal
DOI: 10.1007/s11655-010-0009-z Document Type: Short Survey |
|
Times cited : (6)
|
|
References (1)
|
